For the first time, a new tool developed at Berkeley Lab allows researchers to interactively explore the hierarchical processes that happen in the brain when it is resting or performing tasks. Scientists also hope that the tool can shed some light on how neurological diseases like Alzheimer’s spread throughout the brain.
Berkeley Lab Researchers Discover How and Where Breast Tumor Cells Become Dormant and What Causes Them to Become Metastatic
Berkeley Lab researchers have identified the microenvironment surrounding microvasculature as a niche where dormant breast cancer cells may reside, and the sprouting of microvasculature blood vessels as the event that transforms dormant cancer cells into metastatic tumors.
Berkeley Lab researchers have developed unique fluorescent probes for molecular imaging of copper in the brain, and are using these probes to uncover new information critical to a healthy mind.
Berkeley Lab researchers have constructed the first detailed and complete picture of a protein complex that is tied to human birth defects as well as the progression of many forms of cancer. Knowing the architecture of this protein, PRC2, should be a boon to its future use in the development of new and improved therapeutic drugs.
Berkeley Lab researchers have identified the FAM83A protein as a possible new oncogene and linked it to therapy resistance in breast cancer. This discovery helps explain the clinical correlation between a high expression of FAM83A and a poor prognosis for breast cancer patients, and may also provide a new target for future therapies.
Exciting New Field of Bioorthogonal Chemistry Owes a Debt to Curiosity-Driven Research from Previous Eras
Berkeley Lab Researchers are developing a promising treatment for safely decontaminating humans exposed to radioactive actinides from a major radiation exposure event, such as a nuclear reactor accident or a “dirty bomb” terrorist attack. The treatment, which can be administered as a pill that can result in the excretion of approximately 90-percent of the actinide contaminants within 24 hours, has been advanced through the initial pre-clinical phases.